InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,895.90
(
1.60%
)
Post# of 251706
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DonShimoda

Send PM Follow Ignore
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

DonShimoda

Re: DonShimoda post# 154924

Saturday, 01/05/2013 10:14:33 AM

Saturday, January 05, 2013 10:14:33 AM

Post# of 251706
XOMA -- Poster for XOMA 052 (Gevokizumab) in Resistant Uveitis of Behçet’s Disease

Findings of this pilot trial suggest that IL-1ß plays a major role in Behcet's uveitis. Intraocular inflammation began to resolve in all 7 patients on Day 1, with a median time to first response of 4 days. Five out of 7 patients were in remission by Day 28. One patient, after a single infusion, remained in remission on Day 98. http://bit.ly/13a2zjF

Uveitis of Behçet’s Disease Pilot Trial Results http://bit.ly/Wfmg3k

Development of Immunopathogenesis Strategies to Treat Behçet's Disease
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324914/
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up